Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2016-11-22
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when
given together with dexamethasone in treating patients with multiple myeloma that has
returned after a period of improvement. Dinaciclib and bortezomib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving dinaciclib and bortezomib together with dexamethasone may kill more cancer
cells.